The ability to link T cell antigens, peptides bound by the major histocompatibility complex (pMHC), to TCR sequences is essential for monitoring and treating immune-related diseases. Fluorescently labeled T cell antigen oligomers, such as pMHC tetramers, are widely used to identify antigen-binding T cells 1 . However, spectral overlap limits the number of pMHC tetramer species that can be examined in parallel and the extent of cross-reactivity that can be examined 1 . Time-of-flight mass cytometry (CyTOF) with isotope-labeled pMHC tetramers can interrogate a larger number of antigen species simultaneously, but its destructive nature prevents the linkage of antigens bound to TCR sequences 1 .
DNA-barcoded pMHC dextramer technology has been used for the analysis of antigen-binding T cell frequencies to samples of more than 1,000 pMHCs for T cells sorted in bulk 2 . However, with bulk analysis, information on the binding of single or multiple peptides to individual T cells is lost. In addition, antigen-linked TCR sequences cannot be obtained, which would be valuable for tracking antigenbinding T cell lineages in disease settings, for TCR-based therapeutics development 3 , and for uncovering patterns in TCR-antigen recognition 4 . Another limitation is the high cost and long duration associated with synthesizing peptides chemically 5 , which prevents the quick generation of a pMHC library that can be tailored to specific pathogens or neoantigens in an individual.
To address these challenges, we developed TetTCR-seq for the highthroughput pairing of TCR sequences with potentially multiple pMHC High-throughput determination of the antigen specificities of t cell receptors in single cells We present tetramer-associated T-cell receptor sequencing (TetTCR-seq) to link T cell receptor (TCR) sequences to their cognate antigens in single cells at high throughput. Binding is determined using a library of DNA-barcoded antigen tetramers that is rapidly generated by in vitro transcription and translation. We applied TetTCR-seq to identify patterns in TCR cross-reactivity with cancer neoantigens and to rapidly isolate neoantigen-specific TCRs with no cross-reactivity to the wildtype antigen.
species bound on single T cells. First, we constructed a large library of fluorescently labeled, DNA-barcoded (DNA-BC) pMHC tetramers in a rapid and inexpensive manner using in vitro transcription and translation (IVTT) (Fig. 1a) . Next, tetramer-stained cells were single-cell sorted and the DNA-BC and TCRαβ genes were amplified by RT-PCR ( Fig. 1b) . A molecular identifier (MID) was included in the DNA-BC to provide absolute counting of the copy number for each species of tetramers bound to the cell. Finally, nucleotide-based cell barcodes were used to link multiple peptide specificities with their bound TCRαβ sequences ( Fig. 1b) . DNA-BC pMHC tetramers are compatible with isolation of rare antigen-binding precursor T cells 6 , making TetTCR-seq a versatile platform for analyzing both clonally expanded and precursor T cells.
As constructing large pMHC libraries via ultraviolet-mediated peptide exchange using traditionally synthesized peptide is costly, with long turnaround times 5 , we use a set of peptide-encoding oligonucleotides that serve as both the DNA-BCs for identifying antigen specificities and as DNA templates for peptide generation via IVTT (Fig. 1a) . The IVTT step only adds a few hours once oligonucleotides are synthesized. This substantially reduces the cost (about 20-fold) and time (2-3 d instead of weeks) compared to synthesizing peptides chemically. pMHC tetramers generated by our IVTT method have similar performance to their synthetic-peptide counterparts ( Fig. 1c and Supplementary Figs. 1 and 2) . DNA-BC conjugation did not interfere with staining and has comparable sensitivity to fluorescence readouts ( Supplementary Figs. 3 and 4) . We performed six main TetTCR-seq experiments (Supplementary Fig. 5 ). We first assessed the ability of TetTCR-seq to accurately link TCRαβ sequences with pMHC binding from primary CD8 + T cells in human peripheral blood. In experiment 1, we constructed a 96-peptide library consisting of well-documented foreign and endogenous peptides bound to HLA-A2 (Supplementary Table 1 ) and isolated dominant pathogen-specific T cells, as well as rare precursor antigen-binding T cells, from a healthy cytomegalovirus (CMV)-seropositive donor ( Fig. 1 and Supplementary Figs. 6  and 7) . To test whether TetTCR-seq can detect cross-reactive peptides, we included a documented hepatitis C virus (HCV) wild-type (WT) peptide, HCV-KLV(WT) 7 , and four candidate altered peptide ligands (APL) with one or two amino acid substitutions ( Supplementary  Table 1 ). An established HCV-KLV (WT) T cell clone 7 was spiked into the donor's sample to test its cross-reactive potential.
Bound peptides were classified by an MID threshold derived from tetramer-negative controls and a ratio of MID counts between the peptides above and below this threshold ( Fig. 1d and Supplementary Note). Using this classification scheme, we identified the HCV-KLV(WT) epitope from all spike-in cells sorted ( Fig. 1e and Supplementary Fig. 8 ). In addition, we discovered that all four APLs were also classified as binders. A separate experiment confirmed the b r i e f c o m m u n i c at i o n s binding of these APLs to the T cell clone (Fig. 1f) . These results show that TetTCR-seq is able to resolve positively bound peptides in primary T cells and identify up to five cross-reactive peptides per cell.
Most primary T cells were classified as binding one peptide ( Fig. 1g) . This result is expected because the probability of TCR cross-reactivity between similar peptides is higher than disparate ones 8, 9 . Among the peptides surveyed, we found a high degree of peptide diversity in the foreign-antigen-binding naive T cells (Fig. 1h) . This diversity reduced to two dominant peptides for CMV and influenza in the non-naive repertoire 10 (Fig. 1h) . This is expected given the CMV seropositive status and the high probability of influenza exposure or vaccination for this donor. The majority of cells within the endogenous-antigenbinding population bound MART1-A2L, which corroborates its high documented frequency 6, 10 (Fig. 1h) . Linked TCR and DNA-BC analysis revealed that TCRα V genes 12-2 and 12-1/12-2 dominated in MART1-A2L-and YFV-LLW-specific TCRs, respectively ( Fig. 1i ), EBV_YLQ  EBV_YVL  GLNS_GLL  HCV_L2I  HCV_LLF  HPV_YML  ALADH_VLM  IVPA_FMY  HBV_WLS  HSV_SLP  CMV_MLN  HTLV_LLF  YFV_LLW  IV_GIL  CMV_NLV  IGRP_VLF  MAGEA10_GLY  PPI_15_23  PPI_RLL  GP100_IMD/ITD  ZNT8_LLS  TYR_YMD  CD1_LLG  PD5_KLS which is consistent with other reports 11, 12 . TetTCR-seq on a second CMV-seropositive donor (experiment 2) verified the findings from experiment 1 (Supplementary Fig. 9 ). These results highlight the ability of TetTCR-seq to accurately link pMHC binding with TCR sequences. We next applied TetTCR-seq to study the extent of cancer antigen cross-reactivity in healthy donor peripheral blood T cells and isolate neoantigen (Neo)-specific TCRs with no cross-reactivity to WT counterpart antigen. Naive T cells from healthy donors are a useful source of neoantigen-binding TCRs 3 . However, most neoantigens are one amino acid away from the WT sequence, meaning that neoantigenbinding TCRs may cross-react with host cells to cause autoimmunity.
Although clinical adverse effects caused by neoantigen-recognizing T cells cross-reacting with endogenous tissue have not been reported, possibly owing to the lack of technology development, other forms of cross-reactivity have been reported to cause death in clinical trials 13 . In experiment 3, we surveyed 20 pairs of Neo-WT peptides that bind HLA-A2. Since pMHC tetramers can select T cells reactive to peptides that are not naturally processed, peptides were chosen on the basis of previous evidence of tumor expression and T cell targeting 3,14-16 ( Supplementary Table 4 ). Neo and WT pMHC pools were labeled using two separate fluorophores, allowing sorting of three cell populations: Neo + WT − , Neo − WT + and Neo + WT + ( Fig. 2a and  Supplementary Fig. 10 ).
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AD3 AD4  AD5  AD6  AD7  AD8  AE2  AD10  AD11  BD2  BD3  BD4  BD6  BD7  BD8  BD9  BD10  BD11  BE2  BE3  BE4  BE5  BE6  BE7  AF2  AF3  AF4  AF5  AF6  AF7  AF8  AF9  AF10 b r i e f c o m m u n i c at i o n s T cells with two detected peptide binders accounted for 84% of the Neo + WT + population, 98% of which belonged to a Neo-WT antigen pair (Supplementary Fig. 11 ). All cells with shared TCRαβ amino acid sequence had the same peptide specificity (Supplementary Fig. 12) . Cells in the Neo + WT + population bound 11 of the 20 Neo-WT antigen-pairs, indicating that Neo-WT cross-reactivity is widespread in the precursor T cell repertoire (Fig. 2b) . We noted that neoantigens with mutations at fringe positions 3, 8 and 9 elicited significantly more cross-reactive T cells than the ones at center positions 4, 5 and 6 ( Fig. 2c, P < 0.005 ). This is consistent with previous reports using alanine scanning in a mouse model 17 . TetTCR-seq on a separate donor (experiment 4) showed the same trend (Supplementary Fig. 13g , P < 0.05). Undetected peptides from both experiments were due to their low T cell frequencies (Supplementary Fig. 14) .
To test the feasibility of TetTCR-seq to screen larger libraries, we assembled a library of 157 Neo-WT antigen pairs and profiled T cell cross-reactivity in more than 1,000 tetramer + CD8 + sorted single T cells from two donors (experiments 5 and 6, Fig. 2d and Supplementary  Figs. 15 and 16) . ELISA on all 315 pMHC species showed no difference in pMHC ultraviolet exchange efficiency between detected and undetected peptides (Supplementary Fig. 17 ). As in experiment 3 and 4, neoantigen mutations in the fringes had elevated percentages of cross-reactive T cells relative to mutations in the middle (Fig. 2e,f and Supplementary Fig. 16j ). Using this larger dataset, we also found that neoantigen mutations with high PAM1 values, a surrogate for chemical similarity related to evolutionary mutational probability 18 , had a significantly higher percentage of cross-reactive T cells than those with low PAM1 values ( Fig. 2f , P < 0.005). Thus, in addition to mutation position, WT-binding T cells are more likely to recognize the neoantigen if the mutated amino acid is chemically similar to the original. Additional, so far unaccounted-for variations still exist between peptides, highlighting the necessity for experimental screening against WT cross-reactivity when using neoantigen-based therapy in cancer.
We also assessed the utility of TetTCR-seq for isolating neoantigenspecific TCRs with no cross-reactivity to WT. We generated primary cell lines, each derived from five sorted cells in the Neo + WT − , Neo − WT + and Neo + WT + populations from experiments 3 and 4. These cells lysed antigen-pulsed target cells in a manner that matched their gating scheme during sorting, independent of the choice of pMHC tetramer fluorophore ( Fig. 2g and Supplementary Fig. 18 ). Further TetTCR-seq analysis of Neo + WT − and Neo + WT + T cell lines showed unique TCRs in each cell line targeting a limited range of antigens ( Supplementary  Fig. 19a,b) . Cytotoxicity testing confirmed the cross-reactivity of Neo + WT + cell lines as identified by TetTCR-seq ( Supplementary  Fig. 19c) . Lastly, the antigen recognition of Jurkat76 cell lines transduced with TCRs identified from experiments 3 and 4 matched their original specificities ( Fig. 2h and Supplementary Fig. 20) . Together, our T cell line and TCR-transduced Jurkat experiments show that TetTCR-seq is not only capable of identifying cross-reactive TCRs on a large scale but can also identify functionally reactive neoantigen-specific TCRs that are not cross-reactive to WT peptide in a high-throughput manner, which could be valuable in TCR redirected adoptive cell transfer therapy 3, 19 .
In conclusion, we show that TetTCR-seq can accurately link TCR sequences with multiple antigenic pMHC binders in a highthroughput manner, which can be broadly applied to interrogate antigen-binding T cells in T cell populations, from infection to autoimmune disease and cancer immunotherapy, potentially even for individual patients. With methods emerging for predicting antigenic pMHCs for groups of TCR sequences 4 , TetTCR-seq can not only facilitate development in this area but also help to validate informatically predicted antigens. Lastly, TetTCR-seq can be integrated with single-cell transcriptomics and proteomics to gain further insights into the connections between single T cell phenotype on the one hand and TCR sequence and pMHC-binding landscape on the other 20 .
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We thank B. Wendel for discussions and for producing recombinant HLA-A2; M.M. Davis and H. Huang at Stanford University for discussion of the lentiviral transduction protocol and providing a template TCR construct and HLA-A2 construct; W. Uckert at the Max Delbruck Center for Molecular Medicine for sharing the Jurkat 76 cell line; A. Brock at University of Texas Austin for sharing the HEK 293T cell line; J. Lou at the Institute of Biophysics, Chinese Academy of Sciences, for helping with HCV APL prediction; P. Parker, K. Patel and H. Pan for assistance with initial prototyping; and the NIH tetramer center for additional pMHC tetramer reagents. We also thank anonymous blood donors and staff members at We Are Blood for sample collection. This work was supported by NIH grants R00AG040149 (N.J.), S10OD020072 (N.J.) and R33CA225539 (N. oNLINe MeThoDS PE-or APC-labeled streptavidin conjugation to DNA linker. Conjugation of the DNA linker to PE-or APC-labeled streptavidin was performed following manufacturer's protocols (Solulink). Excess unconjugated DNA linker was removed by six wash steps in a Vivaspin 6 100-kDa protein concentrator (GE Healthcare). Conjugates were concentrated, and then passed through a 0.2-µm centrifugal filter. The molar DNA:protein conjugation ratio was kept between 1:3 and 1:7. DNA:protein conjugation ratio was determined by absorbance using a 1 mg/ml PE-or APC-labeled streptavidin reference solution. The absorbance of the DNA-streptavidin conjugate was then compared with this standard curve to determine the effective protein concentration of the conjugate. The DNA concentration was determined from the difference in the A 260 absorbance between the DNA-streptavidin conjugate and a protein concentration-matched version of the PE or APC streptavidin. pMHC UV exchange and tetramerization. Biotinylated pMHC containing a UV-labile peptide was directly added to the completed IVTT reaction. pMHC UV exchange and tetramerization followed a previously described protocol 5,6 (see Supplementary Note). The UV exchange was performed for 60 min on ice, and then the sample was incubated at 4 °C for at least 12 h. Confirmation of the quality and concentration of UV-exchanged pMHC monomer was assessed by an ELISA assay as described previously 5 . DNAbarcoded fluorescent streptavidin conjugate was then added to its corresponding UV-exchanged pMHC monomer mix at molar ratio of 1:6.7 and incubated at 4 °C for 1 h to produce the final DNA-BC pMHC tetramer. Corresponds to steps 1.3 and 3.1 in Figure 1a .
Generation
DNA-BC pMHC tetramer pooling. 500 µl of staining buffer (PBS, 5 mM EDTA, 2% FBS, 100 µg/ml salmon sperm DNA, 100 µM D-biotin, 0.05% sodium azide) was added to a 100 kDa Vivaspin protein concentrator (GE) and incubated for at least 30 min. The concentrator was spun at 10,000g and further staining buffer was added until 1 ml of solution ran through the membrane. Immediately before cell staining, 0.65 µl of each DNA pMHC tetramer is added to 400 µl of staining buffer, transferred to the concentrator, and then spun at 7,000g for 10 min or longer until the volume reached ~50 µl. Corresponds to Figure 1b, left. pMHC tetramer staining and sorting. Human Leukocyte Reduction System (LRS) chambers were obtained from deidentified donors by staff members at We Are Blood with informed consent. The use of LRS chamber from deidentified donors for this study was approved by the Institutional Review Board of the University of Texas at Austin and is compliant with all relevant ethical regulations. Antigen-specific T cell isolation was performed following a previously established protocol 6 . In brief, CD8 + T cells were isolated from LRS chambers using the RosetteSep CD8 + T cell enrichment cocktail (Stemcell) together with Ficoll-paque (GE Healthcare).
Cells were either kept either on ice or at 4 °C in refrigerator for the remainder of the experiment. In experiments 1, 2, 3 and 5, an HCV-KLV(WT) binding clone, prestained with BV605-CD8a, was spiked into the main sample. Cells were resuspended into staining buffer containing ~60 nM of each DNA-BC pMHC tetramer and 0.025 mg/ml of BV785-CD8a (RPA-T8) antibody and incubated for 1 h at 4 °C. Cells were washed and then incubated with anti-PE and anti-APC microbeads (Miltenyi). After washing, tetramer-staining cells were enriched using an LS column (Miltenyi). The enriched fraction was eluted off the column and washed into FACS buffer containing 0.05% sodium azide, and stained with AF488-CD3, 7-AAD, BV421-CCR7, BV510-CD45RA and BV785-CD8a (BioLegend). The tetramer-depleted flow-through fraction was stained with the same antibody panel. Single cells were sorted using BD FACSAria II into 4 µl lysis buffer following a previously published protocol 7 .
TCR library preparation. Single-cell TCR amplification and sequencing was done following a published protocol 7 with a minor modification. RT was performed on TCR in the same lysis well when DNA-BCs were present. During the first PCR amplification, P1 and P2 primers were included in the primer mix at 100 nM final concentration for concurrent amplification of TCR and the DNA-BC ( Supplementary Table 10 ). During subsequent PCRs, TCR and DNA-BC were amplified separately in parallel wells in 384-well plates. After PCR, multiple cells were pooled, purified by gel electrophoresis and extraction, and then sequenced using Illumina Mi-seq V2 kit. Sequence reads were analyzed following a previous protocol 7 . Corresponds to Figure 1b . DNA-BC library preparation. One microliter of the first PCR product from the TCR and DNA-BC amplification was combined with 100 nM V1f_rxn2 and V1r_rxn2 primers and 0.025 U/µl Ex Taq HS (Takara) to 5 µl volume for a second PCR. PCR proceeded at 95 °C 3 min; then ten cycles of 95 °C 20 s, 55 °C 40 s, and 72 °C 45 s; then 72 °C 5 min. PCR primers include cell barcode sequences to encode wells and a partial Illumina adaptor as previously described 7 .
A third PCR was used to add an Illumina adaptor using ILLU_f and ILLU_r primers. PCR proceeded by the same configuration as the second PCR, but using five cycles. Multiple wells were then pooled and purified by gel electrophoresis and gel extraction. The library was sequenced to a depth of at least 6,000 reads/cell. Refer to Supplementary Table 10 for primer sequences. Corresponds to Figure 1b . DNA-BC sequence processing. Raw reads were filtered based on the constant region of the DNA-BC. Reads were further separated according to cell barcodes. Within each cell barcode, reads with an identical MID sequence were clustered together and a consensus peptide-encoding sequence was built for each cluster. Each cluster represents one MID count.
Clusters were filtered based on the peptide-encoding region to be 25-30 nt in length, and with a Levenshtein distance no greater than 2 from the nearest known DNA-BC sequence. A histogram was then created expressing the percentage of total reads belonging to each group of clusters sharing the same read count. Clusters with low read counts, which occur as a result of sequencing errors, were removed (Supplementary Fig. 7a-c) 21 . The clusters were then collected into their corresponding cell and peptide based on the cell barcode and peptide-encoding DNA sequence, respectively.
Calculation of antigen-binding T cell frequency. The absolute frequency of antigen-binding T cells for peptide a i is calculated as follows: The total CD8 + T cell count was determined by measuring the fraction of CD8 + T cells in the flow-through using 7-AAD with anti-CD3 and anti-CD8 antibodies, multiplied by the total live cell count of flow-through by a cell
